[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT
(stands for [18F] Dihydro-Testosterone), to better find and monitor prostate cancer.
Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen
by the PET scanner. FDHT is a radiotracer that looks for a protein which is present in almost
all prostate cancer cells. The investigators want to find out if we can find and monitor
changes in cancer using a FDHT PET scan.